Immunovant Inc (IMVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.89B
Last updated: Nov 17, 2026 at 4:10 PM ET
Immunovant Inc (IMVT) Statistics
Immunovant (IMVT) has a market cap of $6.89B and an enterprise value of $6.16B. It kept -7173.52% of revenue as net income over the last 12 months. Revenue grew 4334.38% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 10.49% below the market cap, as cash exceeds debt.
| Market Cap | $6.89B |
|---|---|
| Enterprise Value | $6.16B |
| Latest price (Nov 17, 2026) | $33.21 |
Key Dates
The next earnings report is expected on Feb 4, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 4, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | March |
Price Statistics
The stock is up 39.89% over 52 weeks and trades 2.53% above its 50-day average.
| Beta (1Y) | 1.54 |
|---|---|
| 52-Week Change | +39.89% |
| 1-Month Change | +20.24% |
| 3-Month Change | -26.13% |
| 6-Month Change | +26.32% |
| 5-Year Change | +262.81% |
| Total Return (1Y) | +39.89% |
| Total Return (3Y CAGR) | -0.60% |
| Total Return (5Y CAGR) | +33.29% |
| Return vs SPY (1Y) | +28.63% |
| Max Drawdown (1Y) | -40.55% |
| Max Drawdown (3Y) | -69.88% |
| Sharpe Ratio (1Y) | 0.62 |
| Correlation with SPY (1Y) | 0.39 |
| 50-Day Average | $32.39 |
| 200-Day Average | $32.42 |
| 52-Week Range | $21.86 to $45.42 |
| RSI (14 Days) | 54.3 |
| Average Volume (20 Days) | 1.41M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.31x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.31x |
|---|---|
| Quick Ratio | 7.31x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -77.47% over the last 12 months, against a 5-year average of -50.27%.
| Return on Equity (ROE) | -77.47% |
|---|---|
| Return on Assets (ROA) | -66.88% |
| Return on Capital Employed (ROCE) | -77.67% |
| ROE (5Y Average) | -50.27% |
| ROA (5Y Average) | -45.49% |
| ROIC (5Y Average) | -49.47% |
| Asset Turnover | 0.01x |
Scores
IMVT has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $7.09M over the last 12 months.
| Revenue | $7.09M |
|---|---|
| Revenue Growth (YoY) | +4334.38% |
| Operating Income | -$531.30M |
| Pretax Income | -$510.25M |
| Net Income | -$508.96M |
| EBITDA | -$509.88M |
| EBIT | -$510.25M |
| Reported EPS (TTM) | -$2.43 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 86.33% of the $760.97M in total assets.
| Cash and Equivalents | $722.27M |
|---|---|
| Total Debt | $0 |
| Net Cash | $722.27M |
| Net Cash Per Share | $3.49 |
| Working Capital | $656.02M |
| Shareholder Equity | $656.95M |
| Book Value Per Share | $3.18 |
| Total Assets | $760.97M |
| Total Liabilities | $104.02M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $8.00K of capital spending, operating cash flow left -$395.01M of free cash flow.
| Operating Cash Flow | -$395.00M |
|---|---|
| Capital Expenditures | $8.00K |
| Free Cash Flow | -$395.01M |
| FCF Per Share | -$1.91 |
| Depreciation and Amortization | $378.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -7488.36%.
| Operating Margin | -7488.36% |
|---|---|
| Pretax Margin | -7191.73% |
| Net Margin | -7173.52% |
| EBITDA Margin | -7186.40% |
| EBIT Margin | -7191.73% |
| FCF Margin | -5567.47% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -0.76% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -0.76% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IMVT
What is IMVT's market cap?
Immunovant has a market cap of $6.89B. Its enterprise value, which adds debt and subtracts cash, is $6.16B.
How many shares of IMVT are outstanding?
Immunovant has 206.67M shares outstanding. The count is up 19.02% from a year earlier.
Does IMVT pay a dividend?
No. Immunovant does not pay a dividend.
How much debt does IMVT have?
Immunovant has $0 of total debt and $722.27M of cash and equivalents, a net cash position of $722.27M.
IMVT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors